Bill Few Associates Inc. Decreases Stock Holdings in Cencora, Inc. $COR

Bill Few Associates Inc. reduced its position in shares of Cencora, Inc. (NYSE:COR) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,162 shares of the company’s stock after selling 697 shares during the period. Cencora comprises approximately 1.5% of Bill Few Associates Inc.’s portfolio, making the stock its 15th largest position. Bill Few Associates Inc.’s holdings in Cencora were worth $5,146,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Invesco Ltd. raised its stake in Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Cencora by 4,459.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after acquiring an additional 975,362 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after acquiring an additional 787,858 shares in the last quarter. Nuveen LLC acquired a new stake in Cencora during the 1st quarter worth $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Cencora by 144.4% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock worth $206,641,000 after acquiring an additional 439,008 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

COR has been the topic of a number of recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a research note on Wednesday, October 8th. Evercore ISI set a $340.00 price objective on shares of Cencora in a research note on Wednesday. Jefferies Financial Group lifted their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $320.00.

Insider Activity

In other news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. This represents a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,993 shares of company stock worth $16,292,923. Insiders own 10.80% of the company’s stock.

Cencora Stock Up 1.2%

Shares of NYSE:COR opened at $318.01 on Monday. The company has a market cap of $61.66 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 1.49 and a beta of 0.63. The firm’s 50-day simple moving average is $296.99 and its 200-day simple moving average is $291.87. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a fifty-two week low of $221.95 and a fifty-two week high of $319.68.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 earnings per share. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.